{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T08:09:09Z","timestamp":1794643749114,"version":"4.9.1"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,21]],"date-time":"2024-08-21T00:00:00Z","timestamp":1724198400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.ebiom.2024.105323","type":"journal-article","created":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T19:27:23Z","timestamp":1726169243000},"page":"105323","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":69,"special_numbering":"C","title":["Prognostic clinical and biological markers for amyotrophic lateral sclerosis disease progression: validation and implications for clinical trial design and analysis"],"prefix":"10.1016","volume":"108","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4241-5135","authenticated-orcid":false,"given":"Michael","family":"Benatar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1618-3502","authenticated-orcid":false,"given":"Eric A.","family":"Macklin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Malaspina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary-Louise","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eran","family":"Hornstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittoria","family":"Lombardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Renfrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Shepheard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iddo","family":"Magen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8628-5769","authenticated-orcid":false,"given":"Yahel","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6519-7225","authenticated-orcid":false,"given":"Volkan","family":"Granit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey M.","family":"Statland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8999-718X","authenticated-orcid":false,"given":"Jeannine M.","family":"Heckmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Rademakers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline A.","family":"McHutchison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard","family":"Petrucelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corey T.","family":"McMillan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9643-9855","authenticated-orcid":false,"given":"Joanne","family":"Wuu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Benatar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volkan","family":"Granit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey M.","family":"Statland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeannine M.","family":"Heckmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corey T.","family":"McMillan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Elman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Ravits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Katz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaya","family":"Trivedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Swenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ted M.","family":"Burns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Caress","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlayne","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Maiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik P.","family":"Pioro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuen","family":"So","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ebiom.2024.105323_bib1","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/mus.24979","article-title":"ALS biomarkers for therapy development: state of the field and future directions","volume":"53","author":"Benatar","year":"2016","journal-title":"Muscle Nerve"},{"issue":"1","key":"10.1016\/j.ebiom.2024.105323_bib2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s40035-021-00257-y","article-title":"Neurofilament light and heterogeneity of disease progression in amyotrophic lateral sclerosis: development and validation of a prediction model to improve interventional trials","volume":"10","author":"Witzel","year":"2021","journal-title":"Transl Neurodegener"},{"issue":"5","key":"10.1016\/j.ebiom.2024.105323_bib3","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S1474-4422(18)30089-9","article-title":"Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model","volume":"17","author":"Westeneng","year":"2018","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.ebiom.2024.105323_bib4","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1212\/WNL.0000000000009559","article-title":"Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS","volume":"95","author":"Benatar","year":"2020","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.ebiom.2024.105323_bib5","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1056\/NEJMoa2204705","article-title":"Trial of antisense oligonucleotide tofersen for SOD1 ALS","volume":"387","author":"Miller","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.ebiom.2024.105323_bib6","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1093\/brain\/awac394","article-title":"Neurofilament light chain in drug development for amyotrophic lateral sclerosis: a critical appraisal","volume":"146","author":"Benatar","year":"2022","journal-title":"Brain"},{"issue":"7","key":"10.1016\/j.ebiom.2024.105323_bib7","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1002\/acn3.51078","article-title":"Longitudinal biomarkers in amyotrophic lateral sclerosis","volume":"7","author":"Huang","year":"2020","journal-title":"Ann Clin Transl Neurol"},{"issue":"1","key":"10.1016\/j.ebiom.2024.105323_bib8","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcac029","article-title":"Multicentre appraisal of amyotrophic lateral sclerosis biofluid biomarkers shows primacy of blood neurofilament light chain","volume":"4","author":"Thompson","year":"2022","journal-title":"Brain Commun"},{"issue":"4","key":"10.1016\/j.ebiom.2024.105323_bib9","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1136\/jnnp-2012-303768","article-title":"Phosphorylated neurofilament heavy subunit (pNF-H) in peripheral blood and CSF as a potential prognostic biomarker in amyotrophic lateral sclerosis","volume":"84","author":"Boylan","year":"2012","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"12","key":"10.1016\/j.ebiom.2024.105323_bib10","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1212\/WNL.0000000000003741","article-title":"Urinary p75 extracellular domain; A biomarker for prognosis, progression and pharmacodynamic effect in ALS","volume":"88","author":"Shepheard","year":"2017","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.ebiom.2024.105323_bib11","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1038\/s41593-021-00936-z","article-title":"Circulating miR-181 is a prognostic biomarker for amyotrophic lateral sclerosis","volume":"24","author":"Magen","year":"2021","journal-title":"Nat Neurosci"},{"issue":"1\u20132","key":"10.1016\/j.ebiom.2024.105323_bib12","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jns.2009.06.002","article-title":"Low uric acid levels in serum of patients with ALS: further evidence for oxidative stress?","volume":"285","author":"Keizman","year":"2009","journal-title":"J\u00a0Neurol Sci"},{"issue":"12","key":"10.1016\/j.ebiom.2024.105323_bib13","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.2169\/internalmedicine.51.7465","article-title":"Relationships between disease progression and serum levels of lipid, urate, creatinine and ferritin in Japanese patients with amyotrophic lateral sclerosis: a cross-sectional study","volume":"51","author":"Ikeda","year":"2012","journal-title":"Intern Med"},{"issue":"9","key":"10.1016\/j.ebiom.2024.105323_bib14","first-page":"1923","article-title":"Uric acid levels predict survival in men with amyotrophic lateral sclerosis","volume":"259","author":"Paganoni","year":"2012","journal-title":"J\u00a0Neurol"},{"issue":"3","key":"10.1016\/j.ebiom.2024.105323_bib15","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s11011-014-9510-y","article-title":"Serum uric acid level is associated with the prevalence but not with survival of amyotrophic lateral sclerosis in a Chinese population","volume":"29","author":"Zheng","year":"2014","journal-title":"Metab Brain Dis"},{"issue":"9","key":"10.1016\/j.ebiom.2024.105323_bib16","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1001\/jamaneurol.2014.1129","article-title":"Amyotrophic lateral sclerosis outcome measures and the role of albumin and creatinine: a population-based study","volume":"71","author":"Chio","year":"2014","journal-title":"JAMA Neurol"},{"issue":"12","key":"10.1016\/j.ebiom.2024.105323_bib17","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1007\/s10072-017-3138-8","article-title":"Changes in routine laboratory tests and survival in amyotrophic lateral sclerosis","volume":"38","author":"Mandrioli","year":"2017","journal-title":"Neurol Sci"},{"issue":"1-2","key":"10.1016\/j.ebiom.2024.105323_bib18","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1080\/21678421.2016.1214733","article-title":"Serum urate at trial entry and ALS progression in EMPOWER","volume":"18","author":"O'Reilly","year":"2017","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"3","key":"10.1016\/j.ebiom.2024.105323_bib19","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/mus.25950","article-title":"Urate levels predict survival in amyotrophic lateral sclerosis: analysis of the expanded Pooled Resource Open-Access ALS clinical trials database","volume":"57","author":"Paganoni","year":"2018","journal-title":"Muscle Nerve"},{"issue":"1","key":"10.1016\/j.ebiom.2024.105323_bib20","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/nbt.3051","article-title":"Crowdsourced analysis of clinical trial data to predict amyotrophic lateral sclerosis progression","volume":"33","author":"Kuffner","year":"2015","journal-title":"Nat Biotechnol"},{"issue":"1","key":"10.1016\/j.ebiom.2024.105323_bib21","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1080\/14660820510027035","article-title":"Prognostic factors for survival in amyotrophic lateral sclerosis patients treated with riluzole","volume":"6","author":"Paillisse","year":"2005","journal-title":"Amyotroph Lateral Scler"},{"issue":"6","key":"10.1016\/j.ebiom.2024.105323_bib22","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1001\/jamaneurol.2016.6179","article-title":"Serum C-reactive protein as a prognostic biomarker in amyotrophic lateral sclerosis","volume":"74","author":"Lunetta","year":"2017","journal-title":"JAMA Neurol"},{"issue":"1","key":"10.1016\/j.ebiom.2024.105323_bib23","doi-asserted-by":"crossref","first-page":"4374","DOI":"10.1038\/s41598-017-04706-5","article-title":"Adipokines, C-reactive protein and amyotrophic lateral sclerosis - results from a population- based ALS registry in Germany","volume":"7","author":"Nagel","year":"2017","journal-title":"Sci Rep"},{"issue":"1\u20132","key":"10.1016\/j.ebiom.2024.105323_bib24","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0022-510X(99)00210-5","article-title":"The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS study group (Phase III)","volume":"169","author":"Cedarbaum","year":"1999","journal-title":"J\u00a0Neurol Sci"},{"issue":"2","key":"10.1016\/j.ebiom.2024.105323_bib25","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1212\/01.wnl.0000194316.91908.8a","article-title":"Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS","volume":"66","author":"Kimura","year":"2006","journal-title":"Neurology"},{"issue":"7-8","key":"10.1016\/j.ebiom.2024.105323_bib26","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1080\/21678421.2022.2039713","article-title":"Defining cognitive impairment in amyotrophic lateral sclerosis: an evaluation of empirical approaches","volume":"23","author":"McMillan","year":"2022","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"1","key":"10.1016\/j.ebiom.2024.105323_bib27","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jneumeth.2006.05.022","article-title":"Functional monoclonal antibodies to p75 neurotrophin receptor raised in knockout mice","volume":"158","author":"Rogers","year":"2006","journal-title":"J\u00a0Neurosci Methods"},{"issue":"4","key":"10.1016\/j.ebiom.2024.105323_bib28","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1093\/ajcp\/92.4.415","article-title":"A\u00a0monoclonal antibody against nerve growth factor receptor. Immunohistochemical analysis of normal and neoplastic human tissue","volume":"92","author":"Thompson","year":"1989","journal-title":"Am J Clin Pathol"},{"issue":"4","key":"10.1016\/j.ebiom.2024.105323_bib29","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1111\/ene.15237","article-title":"Urinary neopterin: a novel biomarker of disease progression in amyotrophic lateral sclerosis","volume":"29","author":"Shepheard","year":"2022","journal-title":"Eur J Neurol"},{"issue":"6","key":"10.1016\/j.ebiom.2024.105323_bib30","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/BF00377856","article-title":"WHO global project on biological monitoring of chemical exposure at the workplace","volume":"68","author":"Mikheev","year":"1996","journal-title":"Int Arch Occup Environ Health"},{"issue":"2","key":"10.1016\/j.ebiom.2024.105323_bib31","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.neuron.2011.09.011","article-title":"Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS","volume":"72","author":"DeJesus-Hernandez","year":"2011","journal-title":"Neuron"},{"issue":"3-4","key":"10.1016\/j.ebiom.2024.105323_bib32","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1080\/21678421.2016.1267768","article-title":"Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): revised diagnostic criteria","volume":"18","author":"Strong","year":"2017","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"4","key":"10.1016\/j.ebiom.2024.105323_bib33","first-page":"316","article-title":"Temporal course of cognitive and behavioural changes in motor neuron diseases","volume":"95","author":"McHutchison","year":"2023","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"4","key":"10.1016\/j.ebiom.2024.105323_bib34","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1097\/00001648-199507000-00005","article-title":"Dose-response and trend analysis in epidemiology: alternatives to categorical analysis","volume":"6","author":"Greenland","year":"1995","journal-title":"Epidemiology"},{"issue":"1","key":"10.1016\/j.ebiom.2024.105323_bib35","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1136\/jnnp-2021-327129","article-title":"Comparison of CSF and serum neurofilament light and heavy chain as differential diagnostic biomarkers for ALS","volume":"93","author":"Halbgebauer","year":"2022","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"4","key":"10.1016\/j.ebiom.2024.105323_bib36","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/ane.13698","article-title":"Blood biomarkers in ALS: challenges, applications and novel frontiers","volume":"146","author":"Sturmey","year":"2022","journal-title":"Acta Neurol Scand"},{"issue":"6","key":"10.1016\/j.ebiom.2024.105323_bib37","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcad287","article-title":"Urinary biomarkers for amyotrophic lateral sclerosis: candidates, opportunities and considerations","volume":"5","author":"Rogers","year":"2023","journal-title":"Brain Commun"},{"issue":"11","key":"10.1016\/j.ebiom.2024.105323_bib38","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S1474-4422(14)70222-4","article-title":"Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial","volume":"13","author":"Cudkowicz","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.ebiom.2024.105323_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102036","article-title":"Efficacy and safety of CNM-Au8 in amyotrophic lateral sclerosis (RESCUE-ALS study): a phase 2, randomised, double-blind, placebo-controlled trial and open label extension","volume":"60","author":"Vucic","year":"2023","journal-title":"eClinicalMedicine"},{"issue":"5","key":"10.1016\/j.ebiom.2024.105323_bib40","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1177\/1740774519858914","article-title":"Design and analysis of a clinical trial using previous trials as historical control","volume":"16","author":"Schoenfeld","year":"2019","journal-title":"Clin Trials"},{"issue":"3\u20134","key":"10.1016\/j.ebiom.2024.105323_bib41","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1080\/21678421.2021.1879865","article-title":"An old friend who has overstayed their welcome: the ALSFRS-R total score as primary endpoint for ALS clinical trials","volume":"22","author":"van Eijk","year":"2021","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"4","key":"10.1016\/j.ebiom.2024.105323_bib42","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1007\/s13311-022-01271-2","article-title":"Considerations for amyotrophic lateral sclerosis (ALS) clinical trial design","volume":"19","author":"Fournier","year":"2022","journal-title":"Neurotherapeutics"},{"issue":"5","key":"10.1016\/j.ebiom.2024.105323_bib43","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1136\/jnnp-2016-314661","article-title":"What does the ALSFRS-R really measure? A longitudinal and survival analysis of functional dimension subscores in amyotrophic lateral sclerosis","volume":"88","author":"Rooney","year":"2017","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"10","key":"10.1016\/j.ebiom.2024.105323_bib44","first-page":"1713","article-title":"Progression in ALS is\u00a0not linear but is curvilinear","volume":"257","author":"Gordon","year":"2010","journal-title":"J\u00a0Neurol"},{"issue":"5\u20136","key":"10.1016\/j.ebiom.2024.105323_bib45","doi-asserted-by":"crossref","first-page":"414","DOI":"10.3109\/21678421.2016.1140786","article-title":"The ALSFRS as an outcome measure in therapeutic trials and its relationship to symptom onset","volume":"17","author":"Proudfoot","year":"2016","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"3-4","key":"10.1016\/j.ebiom.2024.105323_bib46","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1080\/21678421.2024.2320880","article-title":"The ALSFRS-R Summit: a global call to action on the use of the ALSFRS-R in ALS clinical trials","volume":"25","author":"Genge","year":"2024","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"22","key":"10.1016\/j.ebiom.2024.105323_bib47","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1212\/WNL.0000000000001642","article-title":"Neurofilament light chain: a prognostic biomarker in amyotrophic lateral sclerosis","volume":"84","author":"Lu","year":"2015","journal-title":"Neurology"},{"issue":"1-2","key":"10.1016\/j.ebiom.2024.105323_bib48","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1080\/21678421.2016.1241279","article-title":"Diagnostic and prognostic significance of neurofilament light chain NF-L, but not progranulin and S100B, in the course of amyotrophic lateral sclerosis: data from the German MND-net","volume":"18","author":"Steinacker","year":"2017","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"3","key":"10.1016\/j.ebiom.2024.105323_bib49","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/nan.12511","article-title":"Serum neurofilament light chain levels as a marker of upper motor neuron degeneration in patients with Amyotrophic Lateral Sclerosis","volume":"45","author":"Gille","year":"2019","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"2","key":"10.1016\/j.ebiom.2024.105323_bib50","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1136\/jnnp-2018-318704","article-title":"Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis","volume":"90","author":"Verde","year":"2019","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"2","key":"10.1016\/j.ebiom.2024.105323_bib51","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/ana.26860","article-title":"Biomarker qualification for neurofilament light chain in amyotrophic lateral sclerosis: theory and practice","volume":"95","author":"Benatar","year":"2024","journal-title":"Ann Neurol"}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396424003591?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396424003591?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T15:47:13Z","timestamp":1729093633000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396424003591"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":51,"alternative-id":["S2352396424003591"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2024.105323","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.08.12.24311876","asserted-by":"object"}]},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic clinical and biological markers for amyotrophic lateral sclerosis disease progression: validation and implications for clinical trial design and analysis","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2024.105323","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105323"}}